Contraline Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 60

Contraline General Information

Description

Developer of a male contraceptive product intended to provide non-surgical and reversible birth control procedures. The company's technology implants a non-hormonal, non-surgical, and reversible polymer hydrogel into the vas deferens for contraception and acts as a semi-permeable membrane, blocking sperm while allowing fluids through, enabling users to get a cost-effective approach to contraception easily.

Contact Information

Website
www.contraline.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 818 East Jefferson Street
  • Suite 201
  • Charlottesville, VA 22902
  • United States
+1 (434)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 818 East Jefferson Street
  • Suite 201
  • Charlottesville, VA 22902
  • United States
+1 (434)

Contraline Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Contraline Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Later Stage VC 01-Feb-2025 Completed Generating Revenue
14. Later Stage VC 01-Jul-2023 Completed Generating Revenue
13. Later Stage VC 05-Apr-2022 Completed Clinical Trials - General
12. Later Stage VC (Series A) 20-Oct-2021 Completed Clinical Trials - General
11. Grant 18-Nov-2020 Completed Pre-Clinical Trials
10. Debt - PPP 17-Jul-2020 Completed Pre-Clinical Trials
9. Later Stage VC (Series A) 01-May-2020 Completed Pre-Clinical Trials
8. Seed Round 18-Sep-2018 Completed Startup
7. Seed Round 18-Apr-2017 $2.25M $3M Completed Startup
6. Grant 13-Jun-2016 $50K $755K Completed Startup
To view Contraline’s complete valuation and funding history, request access »

Contraline Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A3
Series A2
Series A1 2,172,728 $0.001000 8% $4.89 $4.89 1x $4.89 30.58%
To view Contraline’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Contraline Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a male contraceptive product intended to provide non-surgical and reversible birth control procedures. The
Drug Discovery
Charlottesville, VA
22 As of 2025

San Luis Obispo, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Contraline Competitors (1)

One of Contraline’s competitors is NEXT Life Sciences, a Venture Capital-Backed company based in San Luis Obispo, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NEXT Life Sciences Venture Capital-Backed San Luis Obispo, CA
You’re viewing 1 of 1 competitors. Get the full list »

Contraline Patents

  • 40

    Total Documents Applications and Grants

  • Total Patents Families

  • 20

    Granted

  • 15

    Pending

  • Expiring in next 12 mo

Contraline Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-D1071200-S1 Device for delivering injectable material Active 05-Jul-2023
US-20230346589-A1 Systems and methods for removing biomaterial implants Pending 28-May-2020
AU-2021273196-A1 Biomaterial compositions and methods of delivery Pending 14-May-2020
CA-3183275-A1 Biomaterial compositions and methods of delivery Pending 14-May-2020
US-20230190515-A1 Biomaterial compositions and methods of delivery Pending 14-May-2020 A61F6/22
To view Contraline’s complete patent history, request access »

Contraline Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Contraline Investors (60)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aurum Venture Partners Venture Capital Minority
Freya Ventures Venture Capital Minority
Cleo Capital Venture Capital Minority
Convergent Ventures (San Francisco) Venture Capital Minority
Evolution VC Partners Venture Capital Minority
You’re viewing 5 of 60 investors. Get the full list »

Ready to get started?

Request a free trial

Contraline FAQs

  • When was Contraline founded?

    Contraline was founded in 2015.

  • Where is Contraline headquartered?

    Contraline is headquartered in Charlottesville, VA.

  • What is the size of Contraline?

    Contraline has 22 total employees.

  • What industry is Contraline in?

    Contraline’s primary industry is Drug Discovery.

  • Is Contraline a private or public company?

    Contraline is a Private company.

  • What is Contraline’s current revenue?

    The current revenue for Contraline is .

  • How much funding has Contraline raised over time?

    Contraline has raised $35.9M.

  • Who are Contraline’s investors?

    Aurum Venture Partners, Freya Ventures, Cleo Capital, Convergent Ventures (San Francisco), and Evolution VC Partners are 5 of 60 investors who have invested in Contraline.

  • Who are Contraline’s competitors?

    NEXT Life Sciences is a competitor of Contraline.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »